CSF1R and familial pancreatic carcinoma: It is encouraging that one clinical trial has already reported that dual PD-1 and CSF-1R blockade may provide durable clinical benefit in patients with chemotherapy-treated and immunotherapy-naïve advanced pancreatic cancer (ClinicalTrials.gov identifier: NCT02526017) [25].